复发性多发性硬化症-话题@MedSci - 梅斯（MedSci）

#复发性多发性硬化症#

9篇内容 | 1217人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1635371, encodeId=eb7c16353e12a, content=<a href='/topic/show?id=7fa842532c0' target=_blank style='color:#2F92EE;'>#复发性多发性硬化症#</a>, objectTitle=JNNP:生酮饮食治疗复发性多发性硬化症的II期研究,安全性、耐受性和潜在临床益处, objectType=article, longId=727308, objectId=ab34e27308f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab34e27308f9, replyNumber=0, likeNumber=145, createdTime=2022-12-18, rootId=0, userName=12498717m73(暂无昵称), userId=eb7322449182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab34e27308f9, moduleTitle=JNNP:生酮饮食治疗复发性多发性硬化症的II期研究,安全性、耐受性和潜在临床益处, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ab34e27308f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1635370, encodeId=ffb316353e095, content=<a href='/topic/show?id=7fa842532c0' target=_blank style='color:#2F92EE;'>#复发性多发性硬化症#</a>, objectTitle=苏格兰药物联盟 (SMC)批准Ponvory (ponsimod)治疗复发性多发性硬化症（内容较少，麻烦补充，谢谢）, objectType=article, longId=220349, objectId=a6392203493e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6392203493e, replyNumber=0, likeNumber=66, createdTime=2021-11-22, rootId=0, userName=12498717m73(暂无昵称), userId=eb7322449182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6392203493e, moduleTitle=苏格兰药物联盟 (SMC)批准Ponvory (ponsimod)治疗复发性多发性硬化症（内容较少，麻烦补充，谢谢）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a6392203493e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1635369, encodeId=f91b163536955, content=<a href='/topic/show?id=7fa842532c0' target=_blank style='color:#2F92EE;'>#复发性多发性硬化症#</a>, objectTitle=Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？, objectType=article, longId=219170, objectId=015e2191e0a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=015e2191e0a9, replyNumber=0, likeNumber=89, createdTime=2022-01-01, rootId=0, userName=12498717m73(暂无昵称), userId=eb7322449182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015e2191e0a9, moduleTitle=Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=015e2191e0a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1635368, encodeId=7627163536864, content=<a href='/topic/show?id=7fa842532c0' target=_blank style='color:#2F92EE;'>#复发性多发性硬化症#</a>, objectTitle=EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好, objectType=article, longId=194711, objectId=2e1a194e1115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e1a194e1115, replyNumber=0, likeNumber=0, createdTime=2021-02-13, rootId=0, userName=12498717m73(暂无昵称), userId=eb7322449182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e1a194e1115, moduleTitle=EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2e1a194e1115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1635367, encodeId=6fca163536e37, content=<a href='/topic/show?id=7fa842532c0' target=_blank style='color:#2F92EE;'>#复发性多发性硬化症#</a>, objectTitle=复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点, objectType=article, longId=187657, objectId=c23618e6572f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c23618e6572f, replyNumber=0, likeNumber=60, createdTime=2020-07-15, rootId=0, userName=12498717m73(暂无昵称), userId=eb7322449182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c23618e6572f, moduleTitle=复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c23618e6572f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1635366, encodeId=d6fa16353666e, content=<a href='/topic/show?id=7fa842532c0' target=_blank style='color:#2F92EE;'>#复发性多发性硬化症#</a>, objectTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, objectType=article, longId=176219, objectId=d8491e621960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8491e621960, replyNumber=0, likeNumber=70, createdTime=2020-02-01, rootId=0, userName=12498717m73(暂无昵称), userId=eb7322449182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8491e621960, moduleTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d8491e621960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1635365, encodeId=86251635365c6, content=<a href='/topic/show?id=7fa842532c0' target=_blank style='color:#2F92EE;'>#复发性多发性硬化症#</a>, objectTitle=MULT SCLER：克拉屈滨可以改善复发性多发性硬化症患者生活质量, objectType=article, longId=110311, objectId=c51711031158, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c51711031158, replyNumber=0, likeNumber=68, createdTime=2018-05-14, rootId=0, userName=12498717m73(暂无昵称), userId=eb7322449182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c51711031158, moduleTitle=MULT SCLER：克拉屈滨可以改善复发性多发性硬化症患者生活质量, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c51711031158)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1635364, encodeId=0c9816353648f, content=<a href='/topic/show?id=7fa842532c0' target=_blank style='color:#2F92EE;'>#复发性多发性硬化症#</a>, objectTitle=NEJM：复发性多发性硬化症治疗奥瑞珠单抗与干扰素β-1a，哪家强？, objectType=article, longId=85090, objectId=262c8509025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262c8509025, replyNumber=0, likeNumber=75, createdTime=2017-09-17, rootId=0, userName=12498717m73(暂无昵称), userId=eb7322449182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262c8509025, moduleTitle=NEJM：复发性多发性硬化症治疗奥瑞珠单抗与干扰素β-1a，哪家强？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=262c8509025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1635363, encodeId=21f1163536373, content=<a href='/topic/show?id=7fa842532c0' target=_blank style='color:#2F92EE;'>#复发性多发性硬化症#</a>, objectTitle=NEJM：治疗复发性多发性硬化症，达珠单抗HYP优于干扰素β-1α, objectType=article, longId=56988, objectId=34c7569889d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34c7569889d, replyNumber=0, likeNumber=80, createdTime=2016-09-16, rootId=0, userName=12498717m73(暂无昵称), userId=eb7322449182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34c7569889d, moduleTitle=NEJM：治疗复发性多发性硬化症，达珠单抗HYP优于干扰素β-1α, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=34c7569889d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

复发性多发性硬化症

2020-05-29

12498717m73(暂无昵称) (审核中...)

前往app查看评论内容

#复发性多发性硬化症#

JNNP:生酮饮食治疗复发性多发性硬化症的II期研究,安全性、耐受性和潜在临床益处

2022-12-18

12498717m73(暂无昵称) (审核中...)

前往app查看评论内容

#复发性多发性硬化症#

苏格兰药物联盟 (SMC)批准Ponvory (ponsimod)治疗复发性多发性硬化症（内容较少，麻烦补充，谢谢）

2021-11-22

12498717m73(暂无昵称) (审核中...)

前往app查看评论内容

#复发性多发性硬化症#

Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？

2022-01-01

12498717m73(暂无昵称) (审核中...)

前往app查看评论内容

#复发性多发性硬化症#

EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好

2021-02-13

12498717m73(暂无昵称) (审核中...)

前往app查看评论内容

#复发性多发性硬化症#

复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点

2020-07-15

12498717m73(暂无昵称) (审核中...)

前往app查看评论内容

#复发性多发性硬化症#

Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点

2020-02-01

12498717m73(暂无昵称) (审核中...)

前往app查看评论内容

#复发性多发性硬化症#

MULT SCLER：克拉屈滨可以改善复发性多发性硬化症患者生活质量

2018-05-14

12498717m73(暂无昵称) (审核中...)

前往app查看评论内容

#复发性多发性硬化症#

NEJM：复发性多发性硬化症治疗奥瑞珠单抗与干扰素β-1a，哪家强？

2017-09-17

12498717m73(暂无昵称) (审核中...)

前往app查看评论内容

#复发性多发性硬化症#

NEJM：治疗复发性多发性硬化症，达珠单抗HYP优于干扰素β-1α

2016-09-16

科室
- - 订阅+
  - 更多科室
工具
服务